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Summary The endocrine and therapeutic effects ofthe aromatase inhibitor fadrozole hydrochloride have been
assessed in 80 post-menopausal patients with recurrent breast cancer after tamoxifen failure. Treatment
allocation was randomly 0.5, 1.0 or 2.0 mg orally b.d. Eight patients were not assessable for response. All
patients were evaluable for toxicity (intent-to-treat analysis). In general, the patients' characteristics were well
balanced between the three randomised groups. The endocrine data from this study previously reported suggest
a dose-related suppression of oestrone, but not oestradiol or oestrone sulphate. The objective response rate was
17% (95% CI 8.9-27.3%) with no complete responders. Fifteen patients (21%) had stable disease (NC) and 45
patients (63%) had progressive disease (PD). The median duration of objective response was 36 weeks. The
median time to treatment failure was 12.7 weeks. The log-rank test showed no statistical difference between the
dosage groups. The main adverse events reported were of mild to moderate severity: nausea in 11 patients
(15%), hot flushes in four (5%) and somnolence in three (4%). No serious adverse events were reported. In
conclusion, fadrozole is a clinically active aromatase inhibitor with a low incidence of side-effects and phase III
clinical trials in post-menopausal women are currently under way.
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Approximately one-third of human breast cancers in the
advanced stage respond objectively to endocrine therapy,
which usually involves oestrogen deprivation or inhibition.
In post-menopausal women, the prime source of oestro-
gens is through the peripheral conversion of androgens by the
aromatase enzyme, mainly in fat and muscle tissues
(Longcope et al., 1978; Longcope, 1982). Inhibition of
aromatase is now accepted as an effective treatment in
post-menopausal breast cancer patients (Dowsett, 1990).
Furthermore, it has been reported that approximately two-
thirds of human breast cancers contain measurable, although
relatively low, aromatase activity (Lipton et al., 1987).
Aminoglutethimide (AG) has been used for a number of
years in the treatment of advanced post-menopausal breast
cancer (Santen et al., 1974). It is an efficient inhibitor of
aromatase, achieving more than 90% inhibition of the
enzyme, as assessed by isotopic infusion techniques (Santen
et al., 1978; Macneill et al., 1992). However, this drug inhibits
cholesterol side-chain cleavage in the adrenal glands (e.g.
Ilf-hydroxylase, 21-hydroxylase, 18-hydroxylase), as well as
inhibition of aromatase (Goss and Gwyn, 1994). The
resulting suppression of steroidogenesis has led to its
combined use with replacement doses of glucocorticoid
(Murray and Pitt, 1985). Moreover, substantial side-effects
associated with the use of AG (even with low doses) have
been reported (Stuart-Harris and Smith, 1984a). This has
resulted in the development of a number of other aromatase
inhibitors, with high selectivity and fewer toxic side-effects.
These new inhibitors may be divided into two groups:
steroidal and non-steroidal compounds. Fadrozole hydro-
chloride, CGS 16949A, a tetrahydroimidazole-pyridine deri-
vative is a non-steroidal inhibitor of aromatase. In preclinical
studies it was found to be 400 times more potent than AG
(Steele et al., 1987). Phase I studies reported an excellent
tolerability (Lipton et al., 1990; Beretta et al., 1990; Santen et
al., 1989). Daily fadrozole doses of 2 mg were associated with
a maximum oestrogen suppression (Lipton et al., 1990;
Beretta et al., 1990). In one study, Santen et al. (1989) have
shown that aldosterone suppression occurred only at
substantially higher doses than those required for maximum
oestrogen suppression (8 and 16 mg day-'). Two phase II
studies did not show a significant difference in toxicity or
response between 1 mg day-' and 4 mg day-1 in one study
or between 1, 2 and 4 mg day-' in the other study (Raats et
al., 1992; Hoeffken et al., 1992). In contrast, our preliminary
clinical investigations with this compound indicated that
there was a dose-related suppression of oestradiol levels
between the doses of 0.6 and 4 mg day-1 and that
aldosterone levels were suppressed by approximately 50%
at the 4 mg day-1 dose (Dowsett et al., 1990; Stein et al.,
1990). In order to clarify this point we decided to conduct a
study with CGS used as second-line therapy in post-
menopausal patients with metastatic breast cancer. Treat-
ment allocation was randomly 1, 2 or 4 mg day-1 orally of
fadrozole. The primary objective was to quantify the dose
relationship of CGS with respect to plasma oestrogen
suppression and a broad spectrum of endocrine analysis.
These results have been recently published (Dowsett et al.,
1994). The secondary objective was to evaluate response, time
to treatment failure, duration of response and tolerability;
these results are reported in this paper.
Patients and methods
This was a double-blind, between-patient comparison of three
doses of fadrozole hydrochloride carried out in four centres:
Royal Marsden Hospital, London (centre 1), Royal Marsden
Hospital, Sutton (centre 2), St George's Hospital, London
(centre 3) and Guy's Hospital, London (centre 4). Treatment
allocation was random, 0.5, 1.0 or 2.0 mg orally b.d., with
the doses being coded until completion of the trial. Patient
numbers were balanced within dosage group and within
centre. The target number of patients was 96, i.e. 32 per
treatment group and 24 per centre. The double-blind nature
of the study was maintained until after statistical analysis of
the clinical and endocrine data. Treatment was continued
until progressive disease was documented.
Post-menopausal women under the age of 80 years with
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recurrent breast cancer (metastatic and locoregional recur-
rence) and who did not respond to or were no longer
responding to tamoxifen were recruited. Patients who had
received adjuvant tamoxifen were eligible if they were
suffering relapse while being treated with adjuvant tamoxifen
for at least 6 months, or if they developed metastatic disease
within 12 months after stopping adjuvant tamoxifen. Post-
menopausal status was defined by one of the following
criteria: 5 years or more since spontaneous menopause; serum
follicle stimulating hormone (FSH) in the post-menopausal
range if less than 5 years after spontaneous menopause;
bilateral oophorectomy; radiation castration. Eligible patients
had to have: oestrogen receptor (ER) positive (according to
the definition of the laboratory involved) or ER unknown;
clinical suitability for endocrine treatment; measurable and/or
evaluable disease; a tamoxifen-free period of at least 4 weeks
before starting fadrozole hydrochloride; a life expectancy >3
months; a performance status (PS) (WHO) <2; no significant
renal or hepatic dysfunction. Patients who had received
cytotoxic chemotherapy for the treatment of their metastases
or for local recurrence were eligible.
Patient ineligibility criteria included CNS metastases,
lymphangitic carcinoma of the lung, metastases occupying
more than a third of the liver with abnormal liver function
tests, other concurrent or previous malignant disease (except
in situ carcinoma of the cervix uteri and adequately treated
basal or squamous cell carcinoma of the skin), concomitant
anti-cancer therapy or endocrine therapy or diuretics and/or
ACE-inhibitors. Patients with endocrine disorders such as
diabetes mellitus, confirmed hypo- or hyperthyroidism,
Cushing's syndrome, Addison's disease (treated or un-
treated) were considered ineligible.
The following disease assessments were made at baseline
and every 3 months thereafter: physical examination,
photographs of all visible lesions, chest radiograph, liver
ultrasound (or CAT scan), bone scintigram and skeletal
radiographs (if indicated).
Toxicity was assessed using WHO criteria (WHO, 1979)
and response was assessed using UICC criteria (Hayward et
al., 1977).
The protocol was approved by the Medical Ethical
Committee of the centres involved.
The patient characteristics (dose of fadrozole, age, disease-
free interval, PS, menopausal status, years post-menopausal,
ER status, metastatic sites, dominant site of metastases and
previous treatment for metastatic disease) are shown in Table
I). In general the three dose groups were well balanced with
respect to all baseline characteristics.
Statistical methodology
The primary objective of this study was to quantify the
dose-response relationship of CGS 16949A 1 mg, 2 mg and
4 mg daily with respect to plasma oestrogen suppression
(oestrone, oestradiol and oestrone sulphate). A one-sided test
of significance was chosen for the calculation of sample size,
setting the (alpha) level of significance at 5% and power (1-
beta) at 90% for detecting as statistically significant an
absolute difference of 40% in oestrone suppression between
any two doses, assuming that the lower dose would induce a
suppression of 50% (from baseline). Under these assump-
tions; in a two-treatment case, a sample size of 26 patients
per arm was calculated as required. Extension to the three
treatment case (three doses) resulted in a sample size estimate
of 32 patients per dose (George, 1988).
The Kaplan-Meier product limit method was used to
estimate time to failure (TTF) and duration of response.
The log-rank test was used to compare the survival
distribution functions between dosage groups for TTF. Data
in the form of contingency tables were evaluated for
statistical significance by Fisher's exact test. The 95%
confidence interval (CI) was calculated.
Results
A total of 80 patients were entered into the study from
October 1988 to March 1991. All patients were evaluable for
toxicity (intent-to-treat analysis). Eight were not assessable
Table I Patient characteristics (by fadrozole dose)
Fadrozole dose
I mg day-l 2 mg day-] 4 mg day-'
No. of patients 25 27 28
Median age, years (range) 68.7 68.3 62.8
(42.3 - 77.2) (42.5 - 80.1) (36.8 - 79.4)
Median disease-free interval (years) 2.0 2.17 2.0
PS 0 - 1 16 24 22
PS 2 9 3 5
PS 3 0 0 1
Menopausal status
Pre 1 0 1
Post 23 27 27
Unknown 1 0 0
Median years post-menopausal 12 18 8
ER status
Positive 11 9 11
Unknown 13 18 17
Negative 1 0 0
Metastatic sites
Viscera 9 11 11
Bone 18 14 17
Soft tissue 20 23 19
Dominant site of metastases
Viscera 9 11 11
Bone 11 6 11
Soft tissue 5 10 6
Previous treatment for metastatic disease
TAM only 16 16 21
CT+TAM 4 3 1
CT only 0 1 0
TAM+MPA 0 1 0
TAM +decadurabolin 0 0 1
CT, chemotherapy; TAM, tamoxifen; MPA, medroxyprogesterone acetate; 40H, 4-hydroxyandrostenedione.Fadrozole hydrochloride and advanced breast cancer
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for response: three had no measurable or evaluable disease,
two received trial treatment for less than 27 days owing to
disease progression, one stopped trial treatment after 6 days
owing to disease progression, one was lost to follow-up and
one had hypercalcaemia the day after the start of the trial
treatment (the was treated with clodronate and withdrawn
from the trial). Thus there were 72 evaluable patients. Of
these, sixteen patients were in retrospect not eligible. One
relapsed on adjuvant tamoxifen given for less than 6 months,
two were premenopausal, in one the menopausal status was
unknown., one was ER negative, two received previous
hormonal therapy other than tamoxifen, in one the PS
(WHO) was grade 3, four received concomitant endocrine
treatment (prednisolone in three, thyroxine in one), three
received concomitant biphosphonate treatment and one
presented with endocrine disorder (diabetes mellitus).
Toxicity
Thirty-six adverse experiences from 21 patients (26%) were
considered to be related to CGS 16949A, the most common
of which was mild to moderate nausea in 11 patients (15%).
The most frequent experiences are reported in Table II. Two
patients were withdrawn from trial treatment owing to poor
tolerance: one because of depression and the other because
of lethargy. No serious adverse experiences were reported.
There was no statistically significant effect on either
plasma sodium or potassium levels at 1 month and 3
months. Minor changes occurred, which were reflected in
the sodium-potassium ratio with a significant difference
between the 1 and 3 month means. Nevertheless, these
differences were not consistent across the dose groups. None
of these small effects on sodium, potassium and the sodium-
potassium ratio were clinically relevant.
Similarly, there was no significant change in cortisol and
aldosterone levels for all these dose groups.
Response
Among clinically evaluable patients (72 patients), 12 patients
(17%) had partial responses (PRs) (95% CI 8.9-27.3%),
with no complete responders. Fifteen patients (21%) had
stable disease (NC) and 45 patients (63%) had progressive
Table II Fadrozole toxicity
Grade I Grade 2 Grade 3
Nausea/vomiting 5 6 0
State of consciousness 3 0 1
(somnolence)
Constipation 2 0 0
Depression 0 0 1
Hot flushes 4 0 0
Table III Response to fadrozole
Fadrozole dose
I mg day-1 2 mg day-' 4 mg day-' Total
PR 3 (13) 4 (17) 5 (20) 12 (17)
NC 2 (9) 9 (38) 4 (16) 15 (21)
PD 18 (78) 11 (46) 16 (64) 45 (62)
Total 23 24 25 72
Data indicate number ofpatients (%).
disease (PD). Response by treatment regimen is shown in
Table III. The median duration of objective response was 36
weeks (calculated from the first day of treatment until the
time of diagnosis of disease progression). The data have not
been presented by dose group because of the small numbers
of patients involved. Among clinically evaluable and eligible
patients (56 patients), nine patients had PR (95% CI 7.6-
28.3%), with no complete responders. Fourteen patients had
NC (25%) and 34 patients (61%) had PD.
Time to treatmentfailure (TTF)
TTF was calculated in days from the first day of treatment to
the date of withdrawal from the trial for any reason (e.g.
disease progression, death, lack of tolerance to treatment).
The median TTF was 12.7 weeks. The log-rank test
showed no statistically significant differences between the
dosage groups. The recording of overall survival was not a
trial objective.
Discussion
This study has shown that fadrozole is a clinically active
aromatase inhibitor with a response rate of 17% (95% CI 9-
27%) in previously treated patients. This confirms experience
in two similar studies with response rates respectively of 23%
(95% CI 12-34%) and 16% (95% CI 12-20%) (Raats et
al., 1992; Hoeffken et al., 1992). For second-line endocrine
therapy these results may be slightly lower than for some
other published reports on aromatase inhibitors, including
aminoglutethimide (Powles, 1983; Stuart-Harris and Smith,
1984b; Miller, 1989) and 4-hydroxyandrostenedione (Goss
and Gwyn, 1994). The confidence intervals, however, in this
study and in the other two (Raats et al., 1992; Hoeffken et
al., 1992) are wide, ranging from 9% to 34%. In addition, a
comparison of response rates from second-line hormonal
therapies used in different studies does not allow conclusions
about the 'best second-line hormonal agent' because of
possible selection bias, including the number of non-
responders to first-line endocrine therapy (Powles, 1983).
Comparative phase III trials are required to answer this
question and these are under way. Moreover, in a trial
comparing fadrozole with tamoxifen as first-line treatment
(Thiirlimann et al., 1995) no statistically significant difference
in terms of response rate emerged between these two agents
(16% and 24% respectively). However, the median time to
failure was shorter with fadrozole compared with tamoxifen
(4.9 months vs 8.3 months), but not statistically significant
(P=0.10).
The response rates in patients receiving 0.5 mg, 1 mg and
2 mg of fadrozole twice daily were respectively 13.1%, 16.7%
and 20.0%. The design of our study and patient numbers
involved do not allow dose-response conclusions to be
drawn. Raats et al. (1992) conducted a study in which the
patients were randomised to receive fadrozole 0.5 mg b.d. or
2 mg b.d. The study was designed in order to detect a 30%
difference in response rate between the two regimens with a
power of 80%; no significant difference was found.
This study has also confirmed that fadrozole is a well-
tolerated agent with a low incidence of side-effects. The small
number of side-effects reported (nausea, somnolence, hot
flushes) were of low WHO grade and a causal relationship
with fadrozole was often uncertain. Two patients stopped
therapy because of side-effects (somnolence, depression) but
again a causal relationship remained uncertain. These side-
effects did not appear to be dose related. Others have also
reported the low incidence of side-effects with fadrozole
(Raats et al., 1992; Hoeffken et al., 1992) and this contrasts
favourably with past experience with aminoglutethimide side-
effects (Stuart-Harris and Smith, 1984b).
In conclusion, fadrozole is a clinically active aromatase
inhibitor with a low incidence of side-effects.Fadrozole hydrochloride and advanced breast cancer
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